These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 25043030)

  • 21. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
    Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
    Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The up-regulation of NDRG1 by HIF counteracts the cancer-promoting effect of HIF in VHL-deficient clear cell renal cell carcinoma.
    Zhang ZY; Zhang SL; Chen HL; Mao YQ; Li ZM; Kong CY; Han B; Zhang J; Chen YH; Xue W; Zhai W; Wang LS
    Cell Prolif; 2020 Jul; 53(7):e12853. PubMed ID: 32537867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions.
    Guinot A; Lehmann H; Wild PJ; Frew IJ
    J Pathol; 2016 Jul; 239(3):365-73. PubMed ID: 27126173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
    Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The multifaceted von Hippel-Lindau tumour suppressor protein.
    Robinson CM; Ohh M
    FEBS Lett; 2014 Aug; 588(16):2704-11. PubMed ID: 24583008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma.
    Salama MF; Carroll B; Adada M; Pulkoski-Gross M; Hannun YA; Obeid LM
    FASEB J; 2015 Jul; 29(7):2803-13. PubMed ID: 25805832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma.
    Lucarelli G; Galleggiante V; Rutigliano M; Sanguedolce F; Cagiano S; Bufo P; Lastilla G; Maiorano E; Ribatti D; Giglio A; Serino G; Vavallo A; Bettocchi C; Selvaggi FP; Battaglia M; Ditonno P
    Oncotarget; 2015 May; 6(15):13371-86. PubMed ID: 25945836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways.
    Selvarajah J; Nathawat K; Moumen A; Ashcroft M; Carroll VA
    Cell Death Dis; 2013 Oct; 4(10):e865. PubMed ID: 24136229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.
    Vanharanta S; Shu W; Brenet F; Hakimi AA; Heguy A; Viale A; Reuter VE; Hsieh JJ; Scandura JM; Massagué J
    Nat Med; 2013 Jan; 19(1):50-6. PubMed ID: 23223005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
    Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
    Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.
    Kucejova B; Peña-Llopis S; Yamasaki T; Sivanand S; Tran TA; Alexander S; Wolff NC; Lotan Y; Xie XJ; Kabbani W; Kapur P; Brugarolas J
    Mol Cancer Res; 2011 Sep; 9(9):1255-65. PubMed ID: 21798997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
    Gao W; Li W; Xiao T; Liu XS; Kaelin WG
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
    Gong K; Zhang N; Zhang K; Na Y
    Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer.
    Chakraborty AA
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):34-42. PubMed ID: 32209418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner.
    Huang Q; Sun Y; Zhai W; Ma X; Shen D; Du S; You B; Niu Y; Huang CP; Zhang X; Chang C
    Oncogene; 2020 Oct; 39(43):6677-6691. PubMed ID: 32943729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
    Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
    Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
    Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
    Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.